Agreements reached under this partnership
Business Alliances- 1
The Company will provide DDS aptamers on a non-exclusive basis, while FUJIFILM Toyama Chemical Co., Ltd. will manufacture the LNPs and perform the aptamer modification, enabling the integrated provision of aptamer-modified LNPs as a CDMO service.
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
The impact on results for the fiscal year ending March 2027 is currently under review. The Company will promptly disclose any matters that require disclosure.
| Item | Details |
|---|---|
| Name of alliance partner | FUJIFILM Toyama Chemical Co., Ltd. |
| Alliance partner's business activities | Research, development, manufacture, sale, export and import of pharmaceuticals and related equipment |
| Alliance partner's location | Chuo-ku, Tokyo |
| Alliance partner's capital | ¥100 million |
| Type of alliance | Business Alliances |
| Details of the alliance | The Company will provide DDS aptamers on a non-exclusive basis, while FUJIFILM Toyama Chemical Co., Ltd. will manufacture the LNPs and perform the aptamer modification, enabling the integrated provision of aptamer-modified LNPs as a CDMO service. |
| Date of board resolution | 6 July 2026 |
| Contract Date | 6 July 2026 |
| Alliance start date | 6 July 2026 |
| Impact on Business Performance | The impact on results for the fiscal year ending March 2027 is currently under review. The Company will promptly disclose any matters that require disclosure. |
Items this document does not state (13)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The agreement is intended to establish a supply system for high-value-added LNPs directed toward target tissues through the use of DDS aptamers, address customer needs in nucleic acid drug development, maximize the commercial value of the platform, and expand revenue opportunities.